Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis

Use of PDE4 inhibitors and combinations thereof for the treatment of cystic fibrosis

US Patent 9480676 · Granted Nov 1, 2016

Estimated economic value: $539,967,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods for treating systemic lupus erythematosus and the use of biomarkers as a2024
3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dion2023
Treatment of immune-related and inflammatory diseases2022
Combination therapies comprising apremilast and Tyk2 inhibitors2022
(+)-2-[1-(3-Ethoxy-4- methoxyphenyl)-2-methylsulfonylethyl]- 4-acetylaminoisoind2022
Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-ac2021
3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dion2021
Treatment of immune-related and inflammatory diseases2021
Methods of treating psoriasis using PD-1 binding antibodies2020
Methods of using (+)- 2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-a2020
3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 2020
3-(4-((4-morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 2019